Hide metadata

dc.date.accessioned2017-06-09T08:14:24Z
dc.date.available2017-06-09T08:14:24Z
dc.date.created2017-05-31T15:31:07Z
dc.date.issued2017
dc.identifier.citationMarangi, Luigi Mirinavciute, Grazina Flem, Elmira Tomba, Gianpaolo Scalia Guzzetta, Giorgio De Blasio, Birgitte Freiesleben Manfredi, Piero . The natural history of varicella zoster virus infection in Norway: Further insights on exogenous boosting and progressive immunity to herpes zoster. PLoS ONE. 2017, 12(5)
dc.identifier.urihttp://hdl.handle.net/10852/55596
dc.description.abstractWe use age-structured models for VZV transmission and reactivation to reconstruct the natural history of VZV in Norway based on available pre-vaccination serological data, contact matrices, and herpes zoster incidence data. Depending on the hypotheses on contact and transmission patterns, the basic reproduction number of varicella in Norway ranges between 3.7 and 5.0, implying a vaccine coverage between 73 and 80% to effectively interrupt transmission with a 100% vaccine efficacy against infection. The varicella force of infection peaks during early childhood (3–5 yrs) and shows a prolonged phase of higher risk during the childbearing period, though quantitative variations can occur depending on contact patterns. By expressing the magnitude of exogenous boosting as a proportion of the force of infection, it is shown that reactivation is well described by a progressive immunity mechanism sustained by a large, though possibly below 100%, degree of exogenous boosting, in agreement with findings from other Nordic countries, implying large reproduction numbers of boosting. Moreover, magnitudes of exogenous boosting below 40% are robustly disconfirmed by data. These results bring further insight on the magnitude of immunity boosting and its relationship with reactivation.en_US
dc.languageEN
dc.publisherPublic Library of Science (PLoS)
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleThe natural history of varicella zoster virus infection in Norway: Further insights on exogenous boosting and progressive immunity to herpes zosteren_US
dc.typeJournal articleen_US
dc.creator.authorMarangi, Luigi
dc.creator.authorMirinavciute, Grazina
dc.creator.authorFlem, Elmira
dc.creator.authorTomba, Gianpaolo Scalia
dc.creator.authorGuzzetta, Giorgio
dc.creator.authorDe Blasio, Birgitte Freiesleben
dc.creator.authorManfredi, Piero
cristin.unitcode185,51,15,0
cristin.unitnameAvdeling for biostatistikk
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1473271
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=PLoS ONE&rft.volume=12&rft.spage=&rft.date=2017
dc.identifier.jtitlePLoS ONE
dc.identifier.volume12
dc.identifier.issue5
dc.identifier.pagecount17
dc.identifier.doihttp://dx.doi.org/10.1371/journal.pone.0176845
dc.identifier.urnURN:NBN:no-58368
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn1932-6203
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/55596/1/Marangi_2017_The.pdf
dc.type.versionPublishedVersion
cristin.articleide0176845


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International